Inmed Pharmaceuticals Inc (INM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the S-4 for Q3 FY2026, filed Jul 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INM SEC filings page.
Inmed Pharmaceuticals Inc (INM) reported $4.9M in revenue for fiscal year 2025, up 7.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Small reported revenue is outweighed by operating spending, leaving InMed reliant on external financing to fund its research business.
Gross margin widened from23.9% in FY2024 to34.5% in FY2025 even as revenue was nearly flat, pointing to margin improvement that was not primarily scale-driven. Net loss remained-$8.2M versus-$7.7M , showing the gross-profit improvement was absorbed by operating expenses.
Operating cash flow and free cash flow were both
Financing cash flow provided
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Inmed Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Inmed Pharmaceuticals Inc held $10.8M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $7.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Inmed Pharmaceuticals Inc scores 41/100 among other emerging companies.
Inmed Pharmaceuticals Inc had 2M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Inmed Pharmaceuticals Inc scores 80/100 among other emerging companies.
Inmed Pharmaceuticals Inc spent $2.9M on research and development in fiscal year 2025, which was 22.6% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Inmed Pharmaceuticals Inc scores 54/100 among other emerging companies.
Inmed Pharmaceuticals Inc reported revenue of $4.9M in fiscal year 2025, against $4.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Inmed Pharmaceuticals Inc scores 55/100 among other emerging companies.
Inmed Pharmaceuticals Inc's operations used $7.8M of cash in fiscal year 2025, against $7.0M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Inmed Pharmaceuticals Inc scores 41/100 among other emerging companies.
Inmed Pharmaceuticals Inc's cash, cash equivalents and investments came to $10.8M at the end of fiscal year 2025, against $2.1M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Inmed Pharmaceuticals Inc scores 89/100 among other emerging companies.
Inmed Pharmaceuticals Inc passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Inmed Pharmaceuticals Inc reported a net loss of $8.2M while operations used $7.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Inmed Pharmaceuticals Inc reported -$3.0M in net income in Q3 2026. This represents a decrease of 39.9% from the same quarter a year earlier. Against the prior quarter it is down 46.3%.
Inmed Pharmaceuticals Inc earned -$0.73 per diluted share (EPS) in Q3 2026. Against the prior quarter it is down 43.1%.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
Inmed Pharmaceuticals Inc held $5.2M in cash as of Q3 2026; long-term debt is not reported for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Inmed Pharmaceuticals Inc's ROE was -43.0% in Q3 2026, measuring profit generated per dollar of shareholder equity. This is down 12.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 21.9 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Inmed Pharmaceuticals Inc invested $1.0M in research and development in Q3 2026. This represents an increase of 140.4% from the same quarter a year earlier. Against the prior quarter it is up 62.2%.
Not reported for Q3 2026.
Not reported for Q3 2026.
INM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'26S-4 | Q2'2610-Q | Q1'2610-Q | Q4'25S-4 | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $820K-26.2% | $1.1M-11.4% | $1.3M+1.7% | $1.3M+7.6% | $1.1M-10.4% | $1.3M+40.2% | $1.3M-44.5% |
| Cost of Revenue | N/A | $636K-2.3% | $717K-7.0% | $728K-32.6% | $1.1M+23.0% | $651K-12.7% | $771K-2.1% | $1.1M-18.0% |
| Gross Profit | N/A | $184K-60.0% | $403K-18.3% | $577K+23.7% | $176K-39.3% | $461K+42.2% | $493K+2222.8% | $466K-70.3% |
| R&D Expenses | $1.0M+140.4% | $631K-29.6% | $582K-16.9% | $833K+26.5% | $425K-35.2% | $895K+46.8% | $700K-45.8% | $659K+5.6% |
| SG&A Expenses | $1.7M+9.9% | $1.6M-5.7% | $1.5M+2.6% | $1.8M0.0% | $1.6M+15.3% | $1.7M+26.0% | $1.5M+15.0% | $1.8M+25.0% |
| Net Income | -$3.0M-39.9% | -$2.0M+21.2% | -$1.7M-2.9% | -$1.8M+7.7% | -$2.1M-23.1% | -$2.6M-74.2% | -$1.7M+33.9% | -$1.9M-472.6% |
| EPS (Basic) | -$0.73+62.4% | -$0.51+86.0% | -$0.44+83.8% | -$0.43+88.3% | -$1.94+45.8% | -$3.64+1.9% | -$2.71+82.2% | -$3.66-1407.1% |
| EPS (Diluted) | -$0.73 | -$0.51 | -$0.44 | -$0.43 | -$1.94 | -$3.64 | -$2.71 | -$3.66 |
| Diluted Shares (Avg) | 4M | 4M | 4M | N/A | 1M | 706,546 | 620,127 | N/A |
Not reported in any period shown, so not listed: Operating Income, EBITDA, Interest Expense, Income Tax.
INM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'26S-4 | Q2'2610-Q | Q1'2610-Q | Q4'25S-4 | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.1M-1.6% | $11.2M+31.6% | $13.4M+27.7% | $15.6M+31.8% | $9.3M | $8.5M-44.3% | $10.5M-4.1% | $11.8M-16.2% |
| Current Assets | $6.9M+7.5% | $8.8M+60.7% | $10.8M+48.4% | $12.9M+48.1% | $6.4M | $5.5M-53.7% | $7.3M-12.2% | $8.7M-23.3% |
| Cash & Equivalents | $5.2M+10.2% | $7.0M+103.4% | $9.3M+67.1% | $10.7M+63.5% | $4.7M-38.4% | $3.4M-64.1% | $5.6M-17.1% | $6.6M-26.3% |
| Short-Term Investments | $42K+2.6% | $43K+4.6% | $43K-0.8% | $43K+0.7% | $41K | $41K-8.3% | $43K+0.6% | $43K-3.1% |
| Inventory | N/A | $948K-14.1% | $891K-27.0% | $961K-22.8% | $814K | $1.1M+48.1% | $1.2M+7.7% | $1.2M-23.0% |
| Accounts Receivable | N/A | $183K-30.3% | $343K+20.6% | $465K+31.8% | $368K | $263K-29.6% | $285K+71.7% | $353K+35.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.2M-0.7% | $1.6M-30.9% | $1.8M-14.5% | $2.1M-18.0% | $2.3M | $2.3M-6.6% | $2.1M-89.9% | $2.6M+29.8% |
| Current Liabilities | $2.2M+20.2% | $1.5M-17.4% | $1.6M+8.3% | $1.8M-6.7% | $1.8M | $1.8M+6.6% | $1.4M+7.2% | $2.0M-1.4% |
| Non-Current Liabilities | $31K-92.7% | $124K-76.6% | $215K-66.0% | $306K-52.6% | $419K | $529K-34.1% | $634K-96.7% | $645K+3931.9% |
| Total Equity | $6.9M-1.8% | $9.6M+55.1% | $11.6M+38.1% | $13.4M+45.9% | $7.0M-36.8% | $6.2M-51.6% | $8.4M+187.7% | $9.2M-23.9% |
| Retained Earnings | -$124.0M-7.4% | -$121.0M-6.8% | -$119.0M-7.4% | -$117.2M-7.5% | -$115.4M | -$113.3M-7.5% | -$110.8M-6.6% | -$109.1M-7.6% |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
INM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'26S-4 | Q2'2610-Q | Q1'2610-Q | Q4'25S-4 | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7M-2.1% | -$2.4M+5.0% | -$1.6M+12.0% | -$1.8M-72.8% | -$1.7M+14.2% | -$2.5M-35.4% | -$1.8M+16.0% | -$1.0M-56.4% |
| Depreciation & Amortization | $52K0.0% | $53K0.0% | $53K-2.5% | $53K-3.7% | $52K-5.6% | $53K-3.7% | $55K-0.5% | $55K+2.4% |
| Stock-Based Compensation | $39K-4.2% | $26K+10.4% | $20K-30.2% | N/A | $40K-26.9% | $23K+26.8% | $29K+15.0% | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$1.0M |
| Investing Cash Flow | N/A | N/A | N/A | $0 | N/A | N/A | N/A | $0+100.0% |
| Financing Cash Flow | $232K-92.1% | $0-100.0% | -$137K-116.4% | $8.2M+4644531.3% | $2.9M | $339K | $838K | $176 |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
INM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'26S-4 | Q2'2610-Q | Q1'2610-Q | Q4'25S-4 | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-4 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 22.5%-19.0pp | 36.0%-3.0pp | 44.2%+7.9pp | 13.9%-10.8pp | 41.5%+15.3pp | 39.0%+36.7pp | 36.3%-31.6pp |
| Net Margin | N/A | -247.3% | -154.2% | -137.1% | -168.1% | -231.6% | -132.7% | -151.0% |
| Return on Equity | -43.0%-12.8pp | -21.1%+20.5pp | -14.9%+5.1pp | -13.3%+7.7pp | -30.2%-14.7pp | -41.6%-30.1pp | -20.0% | -21.0%-18.2pp |
| Return on Assets | -32.5%-9.6pp | -18.1%+12.2pp | -12.9%+3.1pp | -11.5%+4.9pp | -22.9% | -30.3%-20.6pp | -16.0%+7.2pp | -16.4%-14.0pp |
| Current Ratio | 3.12-0.4x | 5.94+2.9x | 6.95+1.9x | 6.99+2.6x | 3.49 | 3.05-4.0x | 5.07-1.1x | 4.41-1.3x |
| Debt-to-Equity | 0.330.0x | 0.17-0.2x | 0.15-0.1x | 0.16-0.1x | 0.32 | 0.38+0.2x | 0.25 | 0.28+0.1x |
| Asset Turnover | N/A | 0.07-0.1x | 0.080.0x | 0.080.0x | 0.14 | 0.130.0x | 0.120.0x | 0.11-0.1x |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -80.2% |
Not reported in any period shown, so not listed: Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Inmed Pharmaceuticals Inc INM | FY2025 | $4.9M | -$8.2M | N/A | $7.4M | 60/100 |
| United Compute Inc SHPH | FY2025 | N/A | -$11.7M | N/A | $2.0M | — |
| Redhill Biopharm RDHL | FY2025 | $286K | -$429K | N/A | $4.4M | — |
| Sunshine Biopharma Inc SBFM | FY2025 | $36.3M | -$6.0M | -16.5% | $4.4M | 59/100 |
| PRF Technologies Ltd. PRFX | FY2025 | $17K | -$5.0M | N/A | $3.4M | — |
| China Pharma CPHI | FY2025 | $4.1M | -$3.2M | -76.9% | $35.3M | 39/100 |
Where Inmed Pharmaceuticals Inc Ranks
Frequently Asked Questions
What is Inmed Pharmaceuticals Inc's annual revenue?
Inmed Pharmaceuticals Inc (INM) reported $4.9M in total revenue for fiscal year 2025. This represents a 7.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Inmed Pharmaceuticals Inc's revenue growing?
Inmed Pharmaceuticals Inc (INM) revenue grew by 7.5% year-over-year, from $4.6M to $4.9M in fiscal year 2025.
Is Inmed Pharmaceuticals Inc profitable?
No, Inmed Pharmaceuticals Inc (INM) reported a net income of -$8.2M in fiscal year 2025.
What is Inmed Pharmaceuticals Inc's gross margin?
Inmed Pharmaceuticals Inc (INM) had a gross margin of 34.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Inmed Pharmaceuticals Inc's return on equity (ROE)?
Inmed Pharmaceuticals Inc (INM) has a return on equity of -60.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Inmed Pharmaceuticals Inc's free cash flow?
Inmed Pharmaceuticals Inc (INM) recorded an outflow of $7.8M in free cash flow during fiscal year 2025. This represents a -11.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Inmed Pharmaceuticals Inc's operating cash flow?
Inmed Pharmaceuticals Inc (INM) recorded an outflow of $7.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Inmed Pharmaceuticals Inc's total assets?
Inmed Pharmaceuticals Inc (INM) had $15.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Inmed Pharmaceuticals Inc's capital expenditures?
Inmed Pharmaceuticals Inc (INM) reported no capital expenditure during fiscal year 2025.
How much does Inmed Pharmaceuticals Inc spend on research and development?
Inmed Pharmaceuticals Inc (INM) invested $2.9M in research and development during fiscal year 2025.
What is Inmed Pharmaceuticals Inc's current ratio?
Inmed Pharmaceuticals Inc (INM) had a current ratio of 6.99 as of fiscal year 2025, which is generally considered healthy.
What is Inmed Pharmaceuticals Inc's debt-to-equity ratio?
Inmed Pharmaceuticals Inc (INM) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Inmed Pharmaceuticals Inc's return on assets (ROA)?
Inmed Pharmaceuticals Inc (INM) had a return on assets of -52.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Inmed Pharmaceuticals Inc's P/E ratio?
Inmed Pharmaceuticals Inc (INM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to March 31, 2026). The market capitalization is $7.4M as of Sep 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Inmed Pharmaceuticals Inc's price-to-sales ratio?
Inmed Pharmaceuticals Inc (INM) trades at 1.5x sales, its market capitalization divided by revenue of $4.9M revenue, FY2025. The market capitalization is $7.4M as of Sep 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Inmed Pharmaceuticals Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Inmed Pharmaceuticals Inc (INM) held $10.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.8M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Inmed Pharmaceuticals Inc's Piotroski F-Score?
Inmed Pharmaceuticals Inc (INM) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Inmed Pharmaceuticals Inc's earnings high quality?
Inmed Pharmaceuticals Inc (INM) reported a net loss of $8.2M while operations used $7.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Inmed Pharmaceuticals Inc?
Inmed Pharmaceuticals Inc (INM) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.